Tag Archives: Basal Cell Carcinoma
FDA approves Cemiplimab as first immunotherapy to treat patients with advanced BCC.
As a monoclonal antibody medication, the FDA has approved cemiplimab (Libtayo) in order to treat patients with advanced BCC (Basal […]
